


Screening for TB in HIV Settings

Neil A Martinson PHRU

> Q of C Meeting February 2006


Low points of 2005: WHO Global TB Report

- 8.8 million new TB cases in 2003
 - 98% in developing countries
- >10% increase since 1997
- Increasing in Africa and E. Europe
 - Fueled by HIV and health system collapse
- 1.8 million deaths
 - Leading cause of death in people with HIV
- DOTS programs detect 42% of cases



Harries et al Int J TB Lung Dis


Differences in TB death rates: South Africa 1996-2001/2



Currently: Passive case finding

- Wait for symptoms to drive patient to attend health service.
- Health service must respond rapidly: DOTS
 - Diagnose TB accurately
 - Treat TB effectively/efficiently

TB in Botswana Pre- and Post- DOTS, Pre- and Post- HIV



Global Tuberculosis Control, WHO Report 2004

Screening

- Identification of people at high risk of serious, common diseases at an early stage using simple tests
- Benefit of early identification (prevent: mort/b, transmission)
- Definitive diagnosis: more complex confirmatory test

Screening for TB?

- 1. Serious problem
 - High incidence of active TB
 - High mortality amd morbidity (receive Rx too late)
 - Duration of symptoms (infectiousness)
- 2. Screening tests
- 3. Effective treatment

Methods of screening

Symptom screen

- Do you have a cough?
 (>2wks, productive, any)
- Are you losing weight?
- Do you have a fever?

Chest Xray

Sputum smear and/ or culture

Symptoms of TB in HIV+, TST+

Symptom	OR (95%CI)	
Cough	1.74 (0.9-3.6)	
Productive cough	8.6 (3.7-20)	
Fever	4.4 (1.4-13.7)	
Night sweats	2.7 (1.2-5.7)	
Loss of weight	1.4 (0.7-2.9)	
Shortness of breath	2.3 (0.9-5.7)	

ACF at PMTCT VCT: Soweto

Symptoms	Odds Ratio	95% CI
Cough > 2 wks	3.3	0.7 – 14.9
Sputum production	5.8	1.3 – 26.6
Haemoptysis	11.4	2 – 64.8
Night sweats	3.8	0.7 – 20.1
Fever	9.4	2.0 - 43.4
Chest pain	3.5	0.7 – 18.9
Weight loss	6.8	1.5 – 31.8

Kali et al JAIDS in press

Active case finding HIV+, TST+

Basis for decision to start TB treatment	n
Smear positive	5
Smear negative culture positive	36
ADA pleural fluid	3
Histological diagnosis	2
Fine needle aspiration	3
Clinical findings	4
TOTAL	53

ACF HIV+ at VCT Cambodia

VCT	8 109	
HIV+	1 228 (15%)	
Screened for TB	450 (37%)	
Active TB	107 (24%)	

Vannarith C MMWR 2005

ACF at VCT in Haiti HIV+ and HIV-

	HIV+	HIV-
VCT	474	853
Cough	128 (27%)	113 (13%)
ТВ	50 (39%)	26 (23%)
Cult + TB	25 (50%)	17 (65%)

PMTCT VCT: Soweto Cont

- 120/370 participants had symptoms suggestive of TB.
- 8 patients had newly diagnosed active TB (2,160/100,000)
- All cases: smear negative, culture positive.
- Lay counsellors: 7 minutes: active TB
 4 minutes without TB


Table 2 Active case finding (ACF) for sputum positive tuberculosis by identification of chronic coughers > 10 years old amongst the Agincourt sub-district permanent population Total permanent population 56 566 Total permanent population > 10 years 38251 Permanent population > 10 years (cough status known) 38127 Chronic coughers identified 600 (1.6%) Did not fit case definition of chronic cough 189 (31.5%) On treatment for TB 22 (3.7%) Not found by TB team 4 (0.7%) Died before TB team arrived 1 (0.2%) Other 18 (3.0%) Confirmed chronic coughers 366 Sputum specimens collected 366 (100%) Results available 340 (92.9%) ACE cases Positive on smear and/or culture 6 (1.8%) Ratio of chronic coughers:sputum positive TB cases 61:1

Pronyk P 2001 Int J TB Lung Dis

ACF Masiphumalele, CT

	Smear +	Cult +	
	% Missed by Passive CF		
HIV +	36%	19%	
HIV -	67%	5%	
	Days prior to TB Treatment		
HIV +	0.7 yrs	1.3 yrs	
HIV -	0.2 yrs	9 yrs	

Duration of infectiousness Free State miners



Corbett E. Am J Resp Care

Is there a benefit?

Treating earlier without severe symptoms

- Mortality?
- Morbidity?
- Transmission?


NO EVIDENCE YET

Randomised trial: Chest X-Ray in miners

	Cases detected (%)	2-month mortality (per 100 py)
Annually	29	23
Semi annually	29	10


Roux S IUATLD Conf 2003


Modelling: Prevalence of TB after ACF with CBVCT




Modelling: Incidence of TB after ACF with CBVCT _







Modelling: South Africa



(b) Trajectory of the TB epidemic, South Africa

1990

2000

Year

(d) Cases averted over 10 years, 1% extra coverage

2010

2020

1600

1400-1200-1000-800-600-400-200-

1980

35000 30000

25000

20000 15000 10000

Jumbar of TB Casses

TB Incidence/100000 per year

Currie CSM 2003 AIDS

Modelling ACF: Sub-Saharan Africa

Strategy	Millions prevented	
	Cases	Deaths
DOTS in Sm neg	0.3	0.4
ACF Symptoms	5.6	2.7
ACF Symptoms 7 years	12.9	5.9
ACF Mini X-ray 7 years	20.5	9.9

Active case finding: Other issues

- Latent infection
- Preventive treatment
- Diagnostic algorithms
- Cost effectiveness
- Targeting high risk groups
- Long term benefits
- Children

REVIEW ARTICLE

Active case finding of tuberculosis: historical perspective and future prospects

J. E. Golub,*† C. I. Mohan,*† G. W. Comstock,† R. E. Chaisson*†

Summary

- 1. High HIV prevalence settings have high rates TB in HIV+ and HIV-
- 2. Feasible for HIV+
- 3. ACF at every consultation for HIV+. Symptom screen followed by culture
- 4. Modelled benefits of population ACF
- 5. Unknowns
 - 1. Added burden on TBCP (labs, personnel etc),
 - 2. Treatment completion rates
 - 3. ? LONG TERM INCIDENCE BENEFIT